Poststatin Lipid Therapeutics: A Review

Area of Science:

• Cardiology
• Pharmacology
• Preventive Medicine

Background:

• Elevated low-density lipoprotein cholesterol (LDL-C) is a primary driver of atherosclerotic cardiovascular disease (ASCVD).
• Statins are the standard first-line treatment for hypercholesterolemia and ASCVD risk reduction.
• A significant patient subset experiences inadequate LDL-C lowering or statin intolerance due to adverse effects.

Purpose of the Study:

• To review current non-statin therapeutic options for LDL-C management.
• To explore emerging novel therapies for further reducing LDL-C and ASCVD risk.
• To provide an overview of advanced treatment strategies beyond statin monotherapy.

Main Methods:

• Literature review of recent cardiovascular outcome trials.
• Analysis of efficacy data for non-statin agents including ezetimibe and PCSK9 inhibitors.
• Exploration of ongoing clinical trials for novel lipid-lowering drugs.

Main Results:

• Ezetimibe and PCSK9 inhibitors have proven effective in significantly reducing LDL-C levels.
• These non-statin therapies demonstrate substantial reductions in ASCVD risk in clinical trials.
• Several novel therapeutic targets and agents are under investigation for future clinical application.

Conclusions:

• Non-statin therapies are crucial for achieving LDL-C targets in statin-intolerant or statin-resistant patients.
• These agents offer significant ASCVD risk reduction, complementing statin therapy.
• The pipeline of novel lipid-lowering therapies holds promise for further advancing cardiovascular disease prevention.